Medtronic plc, a leading global healthcare technology company, announced its financial results for the fourth quarter (Q4) and fiscal year 2024, which concluded on April 26, 2024. The report demonstrated robust financial performance, with notable achievements across various segments of the company, leading to a positive outlook for fiscal 2025.

In Q4, Medtronic achieved a revenue of $8.6 billion, marking a slight increase of 0.5% as reported, and a more significant organic growth of 5.4%. This growth was driven by mid-single digit or higher organic revenue growth across all four of Medtronic's segments. However, the company's GAAP net income and diluted earnings per share (EPS) experienced decreases, primarily due to strategic market changes, one-time events, and the impact of foreign currency fluctuations.

For the fiscal year 2024, Medtronic reported a 3.6% increase in revenue, totaling $32.4 billion, and a 5.2% organic growth. The company generated a robust free cash flow of $5.2 billion, a 14% increase from the previous year, demonstrating efficient capital management and operational excellence. Despite facing challenges such as currency fluctuations and strategic divestitures, Medtronic remained resilient, driven by increased surgical volumes, product approvals, and a broad portfolio of medical technologies.

The Cardiovascular, Neuroscience, Medical Surgical, and Diabetes segments each contributed to the company's durable growth, showcasing innovation and market leadership in areas such as cardiac pacing therapies, minimally invasive surgery products, and diabetes management solutions. Notably, the adoption of the MiniMed™ 780G system in the U.S. and new product cycles across high-growth markets have been pivotal in driving revenue gains.

Medtronic's commitment to shareholder value was further underscored by a dividend increase, marking the 47th consecutive year of dividend growth. The quarterly dividend was raised to $0.70 per share, amounting to an annualized rate of $2.80 per share. This decision reflects confidence in the company's stable cash flow generation and ongoing product innovation.

Looking ahead, Medtronic provided guidance for fiscal year 2025, anticipating organic revenue growth of 4% to 5% and projecting an annual adjusted EPS range between $5.40 and $5.50. The company remains optimistic about its future performance, emboldened by its R&D projects, new product pipelines, and strategic initiatives to enhance global market presence.

In summary, Medtronic's financial performance in the fourth quarter and fiscal year 2024 underscores its strong market position and ability to navigate complex market dynamics. With a well-diversified portfolio, strategic focus on innovation, and commitment to operational excellence, Medtronic is well-positioned for sustainable growth and delivering value to shareholders in the upcoming fiscal year and beyond.